Targeting Brain Cancer Stem Cells in the Clinic

摘要: Malignant gliomas (MG) include glioblastoma multiforme (GBM), the most frequent and aggressive of primary brain tumors (Holland, Proc Natl Acad Sci USA 97:6242–6244, 2000). The standard care for GBM, including surgery followed by radiotherapy chemotherapy with temozolomide, is associated a median overall survival 14.6 months following diagnosis (Reardon et al., J Clin Oncol 24:1253–1265, 2006). identification cancer stem cells has led to great opportunity exploit cell mechanisms inhibit tumor initiation, progression, invasion. Brain – also called initiating or propagating - share features normal neural but do not necessarily originate from cells. Although cancers have only small fraction cells, these been shown in laboratory studies contribute therapeutic resistance, formation new blood vessels supply presence this population can explain recurrence some after chemotherapy, radiation therapy, other current treatments. In fact, few enough give rise recurrent tumor. Viewing through prism hypothesis may fundamentally transform therapeutics translate into improved prognosis patients novel means testing strategies treating that focus on eradication animal models, dendritic immunotherapy drugs target pathways active efficacious against suggesting anti-cancer therapies improve therapy. chapter, we will discuss approaches isolate test resistance We then implications clinic, such as effect prognosis. Finally, explore several